Description
This page contains brief details about the drug eltrombopag, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
Eltrombopag was first approved by the U.S. FDA on November 20, 2008, for treatment of thrombocytopenia, chronic hepatitis C, and patients with severe aplastic anemia.
Mechanism of Action of Eltrombopag
Eltrombopag works by stimulating megakaryocytes (the large bone marrow cells) that are responsible for producing platelets. By raising the number of platelets in the blood, Eltrompag prevents bleeding and bruising.
Uses of Eltrombopag
Eltrombopag has been developed to treat immune (primary thrombocytopenia (ITP) or hepatitis C virus (HCV) infection and also treats low blood counts caused by severe aplastic anemia.
Eltrombopag Dosage available
Eltrombopag is available as a tablet to be taken with an empty stomach (1 hour before or 2 hours after a meal). The usual starting dose of an Eltrombopag tablet is 50 mg once daily. Avoid crushing, opening, or dissolving the tablet; swallow it whole with a glass of water. Take this medication as prescribed by your physician. Avoid dairy foods (such as cheese or butter), milk or milkshakes, antacids, and supplements containing iron, aluminum, magnesium, calcium, selenium, zinc, or calcium for 2 hours after or 4 hours before taking this medication.
